Xenetic Biosciences Inc. is a biopharmaceutical company that focuses on developing novel therapies for life-threatening diseases. Its primary function is the advancement of next-generation biologics by leveraging its innovative and proprietary drug delivery platform technology called PolyXen™. This platform is designed to extend the efficacy and improve the pharmacokinetics of biologic drugs. With a strong emphasis on oncology, Xenetic Biosciences is at the forefront of creating novel therapeutics with the potential to significantly impact the healthcare industry. The company is involved in research and development, aiming to produce targeted therapies that can enhance the standard of care in unmet medical needs. It engages with strategic collaborations and partnerships to spearhead its development programs, maximizing the potential for clinical success. Xenetic Biosciences plays a vital role in the biopharmaceutical sector by contributing to scientific advancements and addressing critical medical challenges. Headquartered in Framingham, Massachusetts, this company represents a key player in the ongoing pursuit of effective and innovative medical treatments.